Xilio Therapeutics (XLO) Common Equity (2020 - 2026)

Xilio Therapeutics has disclosed Common Equity across 7 years of filings, most recently posting $72.3 million for Q2 2026.

• In Q2 2026, Common Equity rose 922.27% year-over-year to $72.3 million; the TTM figure through Jun 2026 stood at $72.3 million (up 922.27% YoY), while the FY2025 annual figure was $35.3 million, up 100.44% from the prior year.
• Common Equity came in at $72.3 million for Q2 2026 at Xilio Therapeutics, roughly flat from $72.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $166.1 million in Q1 2022 to a low of -$8.1 million in Q3 2025.
• Average Common Equity over 5 years is $59.5 million, with a median of $44.7 million recorded in 2023.
• Year-over-year, Common Equity plunged 138.6% in 2025 and soared 922.27% in 2026.
• Over 5 years, Common Equity stood at $105.6 million in 2022, then sank by 65.14% to $36.8 million in 2023, then slumped by 52.21% to $17.6 million in 2024, then soared by 100.44% to $35.3 million in 2025, then jumped by 104.87% to $72.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $72.3 million in Q2 2026, $72.5 million in Q1 2026, and $35.3 million in Q4 2025.